Yu Song

Dr. Yu Song

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
BZBinbin Zhang
Binbin Zhang
JZJianan Zhao
Jianan Zhao
MJMinjie Jiang
Minjie Jiang
DPDandan Peng
Dandan Peng
XDXiaobing Dou
Xiaobing Dou
JSJun-ping Shi
Jun-ping Shi
The prevalence and incidence of metabolic-associated fatty liver disease (MAFLD), a clinically heterogeneous disease whose primary clinical therapies include dietary control and exercise therapy, is increasing worldwide and constitutes a significant medical burden. Gut microbes influence the physiopathological processes of the liver through different mechanisms based on the gut-liver axis. Exosomes are essential carriers of intercellular communication. Most previous studies have focused on adipocyte- and hepatocyte-derived exosomes, while the critical role of microbial-derived exosomes and the molecular mechanisms behind them in MAFLD have received little attention. Therefore, we searched and screened the latest relevant studies in the PubMeb database to elucidate the link between microbial-derived exosomes and the pathogenesis of MAFLD, mainly in terms of insulin resistance, intestinal barrier, inflammatory response, lipid metabolism, and liver fibrosis. The aim was to provide a theoretical framework and support for clinical protocols and innovative drug development.

18 January 2025 in Heliyon
Verified
Journal Article
Open access
YZYing Zhu
Ying Zhu
KZKaiyuan Zhang
Kaiyuan Zhang
ZLZiyue Luo
Ziyue Luo
YSYu Song
Yu Song
XWXinchang Wang
Xinchang Wang
Primary Sjogren's syndrome (pSS) is a prevalent disease in rheumatology and immunology. Anxiety, depression, and other mood disorders are pervasive across diverse sectors of society. Recent theories on the gut-brain axis have elucidated that the gut microbiota considered the second brain of humans, can modulate the central nervous system and behavior by mediating bidirectional response systems, including immunity, vagus nerve, and neuroendocrine pathways. This article reviews recent advancements that explore the mechanism between gut microbiota and emotional disorders in pSS. It aims to provide novel therapies for these emotional disorders in pSS.

26 October 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
QZQuanli Zhu
Quanli Zhu
YLYingchao Liu
Yingchao Liu
YSYu Song
Yu Song
Akkermansia muciniphila extracellular vesicles (AKK-EVs) are being investigated as cell-free treatments for intestinal and metabolic disease, but their therapeutic value depends on what they add beyond whole bacteria, purified microbial components, or alternative carriers. This critical narrative review examines 50 publications available up to 19 July 2026, distinguishing vesicle interventions from studies of associated proteins, whole bacteria, and engineered products. Study-level extraction and domain-based appraisal support the comparison of these preparations. The synthesis addresses product identity, causal attribution, exposure, and therapeutic comparison. Native preparations show activity in epithelial and colitis models, while metabolic findings vary with the preparation and experimental setting. For mucosal disease, the therapeutic aim is sustained functional recovery after disease onset. For liver disease, development depends on establishing whether hepatic benefit persists beyond changes in food intake or body weight and whether it results from intestinal activity or delivery to hepatic cells. Engineered products require evidence that the vesicle carrier improves payload delivery or therapeutic index. Whole-cell human trials and observational measurements of EV-associated proteins provide a clinical basis for comparison, but neither establishes the efficacy or safety of administering isolated AKK-EVs to patients. The evidence supports indication-specific preclinical investigation rather than clinical use. Progression towards human studies requires reproducible batches, disease-relevant functional benefit, route-specific repeat-dose safety, and an advantage over a justified active comparator.